June 26. 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010. the Company’s lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modeling, dose selection and regulatory submissions.
The studies are being conducted by Nucro-Technics, one of Canada’s leading providers of IND-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat and dog systems. Using both hepatocytes and liver microsomes provides complementary information because each system captures different aspects of liver metabolism. This approach is intended to help the Company compare broader cell-based metabolic activity with enzyme-focused metabolism, with the aim of providing a more complete understanding of how ONC010 is processed across relevant test systems. The work forms part of Onco-Innovations’ integrated IND-enabling development strategy and complements ongoing ADME, bioanalytical, manufacturing, formulation and clinical translation activities.
“Hepatocyte and microsome studies are foundational components of modern oncology drug development. The data generated are intended help characterize the metabolic profile of ONC010 and to potentially contribute to dose selection, safety assessment and overall development planning,” Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations.
“The initiation of IND-enabling preclinical studies marks an important milestone as the Company advances ONC010 toward our First in Human Study. Understanding how the molecule behaves across relevant species is critical for designing future toxicology studies and informing clinical translation strategies,” stated Thomas O’Shaughnessy, Chief Executive Officer of Onco-Innovations.
